TABLE 3.
Extrapolating distribution of clinical characteristics data for estimate of budget impact
| Percentage | Estimatea | |
|---|---|---|
| RIDOC population | 100 % | 3227 |
| HCV Ab (+) | 26 % | 836 |
| HCV RNA (+) | 67 % | 559 |
| Sentenced population with 6 months or more remaining | 58 % | 327 |
| Treatment naive | 71 % | 232 |
| Treatment experienced | 29 % | 95 |
| Estimated distribution of genotype among HCV RNA (+) | ||
| Genotype 1 | 69 % | 225 |
| Genotype 2 | 8 % | 25 |
| Genotype 3 | 18 % | 57 |
| Genotype 4 | 6 % | 20 |
| Estimated distribution of staging by genotype | ||
| Stage 0 | 9 % | 30 |
| Genotype 1 | 20 | |
| Genotype 2 | 2 | |
| Genotype 3 | 5 | |
| Genotype 4 | 2 | |
| Stage 1–2 | 55 % | 178 |
| Genotype 1 | 123 | |
| Genotype 2 | 13 | |
| Genotype 3 | 31 | |
| Genotype 4 | 11 | |
| Stage 3–4 | 36 % | 119 |
| Genotype 1 | 82 | |
| Genotype 2 | 9 | |
| Genotype 3 | 21 | |
| Genotype 4 | 7 | |
aEstimates based on weighted percentages applied to cross-sectional census of RIDOC population as of February 2014. Percentages may not sum to 100 % due to rounding. Genotype distribution was applied to estimated number of chronic infections. Staging distribution was applied to estimated genotype frequencies. Treatment history was estimated among all HCV Ab(+) individuals